Eli Lilly Rebounds From 20-Day Support as Uptrend ContinuesEli Lilly and CompanyBATS:LLYfinvestnomicsLLY is rebounding after retracing to its 20-day moving average, with buyers stepping in to support the trend. The stock remains in a strong uptrend, making higher highs and higher lows while trading above its well-aligned 20- and 50-day moving averages. Eli Lilly & Co. is a $1.14 trillion market-cap pharmaceutical company engaged in the discovery, development, manufacture, and commercialization of innovative medicines. Its portfolio spans key therapeutic areas, including diabetes, oncology, immunology, neuroscience, and other specialty treatments, supported by a strong pipeline of next-generation therapies. LLY is a wide economic moat company that has delivered significant and consistent revenue and earnings-per-share growth over the past three quarters. The company continues to generate exceptional profitability, with operating and net margins of 49% and 37%, respectively. Return on equity stands at 108%, while return on invested capital is 42%. The balance sheet remains solid, with a current ratio of 1.5x and a debt-to-equity ratio of 1.4x.